Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Acupuncture for Heel Pain Syndrome

Clinical Research on Acupuncture at the Heel Pain Point for the Treatment of Heel Pain Syndrome

The main goal of this study is to determine whether acupuncture at the Heel Pain Point, a distal acupuncture point located on the palm, is an effective and safe treatment for heel pain syndrome. This randomized controlled trial compares Heel Pain Point acupuncture with manual therapy and sham acupuncture to evaluate both clinical efficacy and functional recovery. Specifically, the researchers aim to:

Measure Pain Relief: Evaluate whether Heel Pain Point acupuncture provides greater pain reduction than manual therapy and sham acupuncture using the Visual Analog Scale (VAS).

Assess Walking Function: Determine whether the intervention improves gait performance and foot function through three-dimensional gait analysis and the Maryland Foot Score.

Evaluate Immediate and Long-term Effects: Examine the immediate analgesic effect after each treatment session and the sustained clinical benefits after completion of treatment and at the 3-month follow-up.

Ensure Safety: Monitor adverse events and treatment-related complications throughout the study to evaluate the safety of the intervention.

Target Population

The study is recruiting participants who meet the following criteria:

Age: Adults between 40 and 70 years. Diagnosis: Individuals diagnosed with heel pain syndrome, primarily plantar fasciitis, according to the established diagnostic criteria.

Disease Duration: No specific restriction on disease duration is stated; however, participants must not have received related treatment within the preceding 2 months.

Typical Symptoms: Participants with characteristic medial plantar heel pain, particularly during the first steps after rest, localized tenderness at the calcaneal attachment of the plantar fascia, a positive Windlass test, limited ankle dorsiflexion, or abnormal foot posture.

Exclusions: Individuals with gout, heel trauma, osteomyelitis, purulent inflammation, severe neurological deficits, conditions that may interfere with outcome assessment, contraindications to acupuncture, a history of adverse reactions to acupuncture, pregnancy or plans to conceive, or other conditions considered unsuitable by the investigators.

Primary Research Endpoint The primary endpoint is designed to determine whether Heel Pain Point acupuncture provides superior immediate pain relief compared with manual therapy and sham acupuncture.

Pain Response Rate: The primary efficacy endpoint is the proportion of participants achieving at least a 50% reduction in VAS pain score from baseline at 10 minutes after the first intervention.

Pain Intensity: Changes in VAS scores will be assessed at baseline, 10 minutes after each of the seven treatment sessions, and 3 months after completion of the treatment course.

Objective Functional Recovery: Three-dimensional gait analysis will evaluate changes in gait speed, single-leg stance stability, foot axis and progression angle, initial contact angle, push-off angle, and ground clearance. Foot function will also be assessed using the Maryland Foot Score.

Evaluation Timing: VAS scores and three-dimensional gait parameters will be assessed at baseline, 10 minutes after each treatment session, and at the 3-month follow-up. Clinical efficacy and Maryland Foot Scores will be assessed at baseline, after completion of the seven-session treatment course, and at the 3-month follow-up.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

150

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Tianjin, Kina
        • The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Meeting the aforementioned Western medicine diagnostic criteria for heel pain.
  2. Age between 40 and 70 years, with no relevant treatment received within the preceding 2 months.
  3. Voluntary provision of informed consent and willingness to receive the corresponding treatments.
  4. Presence of calcaneal spurs on X-ray radiography is permitted.

Exclusion Criteria:

  1. Presence of gout, trauma, osteomyelitis, or purulent inflammation in the affected area.
  2. Concomitant history of heel trauma with localized redness, swelling, heat, and inflammatory reactions.
  3. Chronic conditions that may confound treatment efficacy or outcome interpretation (e.g., cardiovascular disease, diabetic neuropathy, fibromyalgia, rheumatoid arthritis, dementia, epilepsy, or other disqualifying conditions).
  4. Radicular pain accompanied by lower extremity muscle weakness, sensory loss, diminished reflexes, progressive neurological deficits, or severe neurological symptoms.
  5. Contraindications to acupuncture (e.g., hemorrhagic diseases, coagulopathy, history of anticoagulant therapy, severe diabetes with infection risk, severe cardiovascular disease).
  6. History of adverse reactions to acupuncture or alcohol allergies.
  7. Currently pregnant or planning to conceive.
  8. Deemed unsuitable for study inclusion by the investigators.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Acupuncture Group

Acupoint Selection: Contralateral point selection (i.e., the left heel pain point is selected for right heel pain, and vice versa).

Heel Pain Point: Located on the palm, 0.8 cun distal to the Daling acupoint (PC7, located on the anterior aspect of the wrist, in the depression of the distal wrist crease, between the tendons of palmaris longus and flexor carpi radialis), toward the thenar eminence.

Primary Needles: Hwato brand (0.25 × 40 mm, Suzhou, China). Primary Patch: Spunlace non-woven hollow patch (with cotton) (5 × 5 cm, ring diameter 2.3 cm, cotton diameter 1.5 cm, Yingrui Pharmaceuticals).

The patient is instructed to sit with both hands fully exposed. The practitioner applies the non-woven hollow patch over the skin. Using a 0.3 × 40 mm sterile filiform needle, the practitioner pierces the hollow patch and inserts the needle obliquely downward at a 30°-45° angle to the skin, reaching a depth of 10-15 mm at the heel pain point. An even reinforcing and reducing manipulation (Ping Bu Ping Xie) is applied with small-amplitude, uniform lifting, thrusting, and twirling. Needle insertion stops upon the arrival of Deqi (sensation of soreness, numbness, distension, or pain). The patient is instructed to move, rotate, and stomp the affected heel for 1-2 minutes. After stomping, manipulation ceases; once the numbness in the foot subsides, the patient may stand or walk slowly to assess pain relief. During the procedure, the patient should concentrate on the heel pain, and the operator will periodically monitor for any discomfort. Needles are retained for approximately 15 minutes,

Aktiv komparator: Manual Therapy Group

Participants lie supine with the affected lower limb relaxed. Manual therapy consists of: (1) thumb kneading and pressure applied to the painful plantar region for 5-10 minutes according to patient tolerance; (2) horizontal stretching by stabilizing the heel while dorsiflexing the ankle to stretch the Achilles tendon and triceps surae (5-10 repetitions, 30 s each); (3) straight-leg raise stretching with ankle dorsiflexion until gastrocnemius tension is achieved; and (4) clockwise and counterclockwise ankle rotation (3 circles each), repeated 3-4 times for 30 s. Treatments are administered every other day for seven sessions.

  1. Kneading and pressing techniques are applied to the affected area using the thumb, with intensity tailored to patient tolerance; focus is placed on localized cord-like structures or fibrous nodules for 5-10 min per session.
  2. Horizontal Stretching: With the patient supine and the lower limb extended, the practitioner stabilizes the heel with one hand and pushes the forefoot with the base of the other palm, maximally dorsiflexing the ankle until tension is felt in the Achilles tendon and triceps surae. This stretch is performed 5-10 times for 30 seconds each.
  3. Straight-Leg Raise Stretching: The practitioner elevates the affected limb while maintaining knee extension. With the left hand on the heel and the right hand gripping the forefoot, the practitioner leans backward to dorsiflex the ankle until gastrocnemius tension is felt.
  4. Ankle Rotation: Building upon step (3), the right hand rotates the forefoot around the heel clockwise and counterclockwise, three circles each.
Sham-komparator: Sham Acupuncture Control Group

Acupoint Selection: Contralateral point selection (i.e., the left heel pain point is selected for right heel pain, and vice versa).

Heel Pain Point: Located on the palm, 0.8 cun distal to the Daling acupoint (PC7, located on the anterior aspect of the wrist, in the depression of the distal wrist crease, between the tendons of palmaris longus and flexor carpi radialis), toward the thenar eminence.

Primary Needles: Hwato brand (0.25 × 40 mm, Suzhou, China). Primary Patch: Spunlace non-woven hollow patch (with cotton) (5 × 5 cm, ring diameter 2.3 cm, cotton diameter 1.5 cm, Yingrui Pharmaceuticals).

The patient is instructed to sit with both hands fully exposed. The practitioner applies the non-woven hollow patch over the skin. Using a 0.25 × 40 mm sterile filiform needle, the practitioner passes the needle through the lower part of the patch and positions it obliquely against the skin at a 30°-45° angle without penetration. A second patch is applied to secure the needle. No needle manipulation is performed, and no attempt is made to elicit Deqi. The patient is instructed to move and rotate the affected foot and gently stomp the heel for 1-2 minutes. Once any numbness or tingling has subsided, the patient may stand or walk slowly to assess pain relief. During the procedure, the patient is asked to concentrate on the heel pain, and the practitioner periodically monitors for discomfort. The sham needle is retained for approximately 15 minutes and then removed.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pain response rate: (the response rate is defined as the proportion of subjects achieving a ≥ 50% reduction in VAS scores from baseline).
Tidsramme: Assessed at 10 minutes after the first intervention

VAS Score: A 10-cm visual analog scale where 0 represents no pain and 10 represents severe pain (1-3: mild; 4-6: moderate; 7-10: severe).

Assessed at 10 minutes after the first intervention

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pain response/remission rate
Tidsramme: These will be recorded and evaluated at baseline, upon completion of 1 treatment course, and at 3 months post-treatment

Clinical Remission Criteria: Based on the Criteria of Diagnosis and Therapeutic Effect of Diseases and Syndromes in Traditional Chinese Medicine (State Administration of Traditional Chinese Medicine).

Cured: Free walking, no mobility restrictions, complete resolution of heel pain.

Markedly Effective: Nearly normal walking, mild discomfort only after prolonged walking, significant improvement in mobility, basic resolution of heel pain.

Effective: Slight restriction during walking/activity, mild heel pain. Ineffective: Persistent restriction in walking/activity, no relief in heel pain.

Total Effective Rate = (Cured + Markedly Effective + Effective) / Total Cases ×100%.

These will be recorded and evaluated at baseline, upon completion of 1 treatment course, and at 3 months post-treatment
Functional improvement(Assessed via the Maryland Foot Score.)
Tidsramme: These will be recorded and evaluated at baseline, upon completion of 1 treatment course, and at 3 months post-treatment

Maryland Foot Score: Evaluates pain, function, appearance, and mobility. Higher scores indicate better foot function (Excellent: 90-100, Good: 75-89, Fair: 50-74, Poor: <50).

These will be recorded and evaluated at baseline, upon completion of 1 treatment course, and at 3 months post-treatment
Changes in VAS Scores
Tidsramme: at baseline, 10 minutes after each of the seven treatment sessions, and 3 months after completion of the treatment course.

The VAS utilizes a 10-cm visual analog scale, where 0 represents no pain and 10 represents severe pain. the pain response rate, defined using the same criterion as the primary outcome,

at baseline, 10 minutes after each of the seven treatment sessions, and 3 months after completion of the treatment course.
Three-dimensional Gait Analysis
Tidsramme: These parameters will be assessed at baseline, 10 minutes after each of the seven treatment sessions, and 3 months after completion of the treatment course.

This study utilizes the "Right Gait Posture" Medical 3.0 dynamic gait analysis system (Shenzhen Xingzheng Technology Co., Ltd., China), selecting six parameters to evaluate the patient's walking ability: gait speed, single-leg stance stability, changes in foot axis and progression angle, initial contact angle, push-off angle, and ground clearance.

These parameters will be assessed at baseline, 10 minutes after each of the seven treatment sessions, and 3 months after completion of the treatment course.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

15. oktober 2026

Primær fullføring (Antatt)

30. oktober 2027

Studiet fullført (Antatt)

30. oktober 2027

Datoer for studieregistrering

Først innsendt

13. mai 2026

Først innsendt som oppfylte QC-kriteriene

19. mai 2026

Først lagt ut (Faktiske)

26. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

14. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. oktober 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere